Homburger advised Zürcher Kantonalbank on the issuance of EUR 500 m Bail-in Bonds
On June 17, 2026, Zürcher Kantonalbank (ZKB) successfully completed a further offering of Bail-in Bonds in the amount of EUR 500 m. Zürcher Kantonalbank’s Bail-in Bonds, including the newly placed EUR 500 m 3.622% 6NC5 Bail-in Bonds, have been designed and issued on the basis of a legal framework allowing Cantonal Banks to issue Total-Loss-Absorbing-Capacity …
Continue reading “Homburger advised Zürcher Kantonalbank on the issuance of EUR 500 m Bail-in Bonds”
Homburger advised Idorsia Ltd in connection with its new up to CHF 250 m secured financing
On June 9, 2026, Idorsia Ltd (SIX: IDIA), a commercial-stage biopharmaceutical company with a portfolio of first- or best-in-class assets, entered into a senior secured term loan agreement of up to CHF 250 million with investment funds managed by Pharmakon Advisors, LP. The first tranche of CHF 150 million will be used, among other things, …
Homburger advised TGS on its acquisition of Apparition Geoservices
On June 8, 2026, TGS, a leading global provider of energy data and intelligence, announced its acquisition of Apparition Geoservices GmbH, securing exclusive access to its proprietary simultaneous source acquisition and separation technology.
Homburger advised UBS AG, acting through its London branch, on its issuance of EUR 1.25 bn in aggregate principal amount of senior notes under its Euro Note Programme
On June 1, 2026, UBS AG, acting through its London branch, successfully completed its issuance of EUR 1.25 bn in aggregate principal amount of Fixed Rate/Floating Rate Notes due 2032 under its Euro Note Programme.
Homburger advises Temenos on the acquisition of additiv
On June 8, 2026, Temenos AG (SIX: TEMN), a global leader in banking technology, announced the acquisition of additiv AG, a Swiss fintech company providing a specialist platform to orchestrate financial services. The transaction is subject to customary closing conditions. The consideration will be paid c.50% in cash and c.50% in equity.
Homburger advised UBS AG, acting through its Stamford branch, on its 3(a)(2) offering of USD 1.5 bn Senior Notes
On May 29, 2026, UBS AG, acting through its Stamford branch, successfully completed its issuance of USD 1.5 bn in aggregate principal amount of 4.678% Fixed-to-Floating Rate Senior Notes due 2030 under its medium-term notes program. The notes were offered and sold in reliance on (i) an exemption from registration provided by Section 3(a)(2) of …
Homburger advises PPG on its issuance of CHF 320 m in inaugural two-tranche CHF offering
On June 3, 2026, PPG Industries, Inc. issued bonds in Switzerland in the aggregate amount of CHF 320 m. The CHF offering was comprised of CHF 180 m aggregate principal amount of 1.2175% notes due 2030 and CHF 140 m aggregate principal amount of 1.6648% notes due 2034.
Homburger advises Amazon on its issuance of CHF 2.82 bn in inaugural six-tranche CHF offering
On May 28, 2026, Amazon.com, Inc. issued bonds in Switzerland in the aggregate amount of CHF 2.82 bn. The CHF offering was comprised of CHF 900 m aggregate principal amount of 0.8350% notes due 2029, CHF 585 m aggregate principal amount of 1.200% notes due 2032, CHF 475 m aggregate principal amount of 1.4475% notes …
Homburger advised Raiffeisen Schweiz Genossenschaft on the issuance of its CHF 200 m 1.44 per cent. digital bail-in bond due 2033
On May 20, 2026, Raiffeisen Schweiz Genossenschaft successfully placed its inaugural digital bail-in bond on the Swiss capital market. The bond will be traded on the SIX Swiss Exchange.
Homburger advises Eli Lilly on the acquisition of LimmaTech Biologics
On May 26, 2026, Eli Lilly and Company (NYSE: LLY) announced the acquisition of LimmaTech Biologics AG for up to USD 780 m in cash, inclusive of an upfront payment and additional potential payments based upon the achievement of certain clinical and regulatory milestones. LimmaTech Biologics is developing vaccines against bacterial pathogens for which rising …
Continue reading “Homburger advises Eli Lilly on the acquisition of LimmaTech Biologics”